Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early versus late intravitreal Conbercept for macular edema due to branch retinal vein occlusion
ChiCTR1800018245Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Oct 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of conbercept in branch retinal vein occlusion (BRVO) (2 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: Best corrected visual acuity at month 6 and Central foveal thickness at month 6. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
conbercept
03
Conditions
branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on ChiCTR1800018245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018245.